IMFINZI
Live / Registered — Registered — international registration renewed (as of 02 Oct 2024)
What this means for you
Registered since 12 Jun 2018. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 12 Jun 2028: the §71 ten-year affidavit of use).
Record
- Serial number
- 79218364
- Registration number
- 5488935
- Mark type
- Design + words
- Filed
- 24 Aug 2017
- Published for opposition
- 27 Mar 2018
- Registered
- 12 Jun 2018
- Next maintenance filing
- §71 ten-year affidavit of use, due by 12 Jun 2028 (grace period to 12 Dec 2028)
- Attorney of record
- Cara M. Kearney
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for use in oncology
Owner
- AstraZeneca AB, Södertälje, SE
- AstraZeneca AB, Södertälje, SE
- AstraZeneca AB, Södertälje, SE
Prior registrations
Prosecution history
- 02 Oct 2024 — NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
- 02 Oct 2024 — REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
- 23 Sept 2024 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 08 Jan 2024 — TEAS SECTION 71 & 15 RECEIVED
- 12 Jun 2023 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 12 Oct 2018 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 21 Sept 2018 — FINAL DISPOSITION NOTICE SENT TO IB
- 21 Sept 2018 — FINAL DISPOSITION PROCESSED
- 12 Sept 2018 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 12 Jun 2018 — REGISTERED-PRINCIPAL REGISTER
- 27 Mar 2018 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 27 Mar 2018 — PUBLISHED FOR OPPOSITION
- 07 Mar 2018 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 22 Feb 2018 — ASSIGNED TO LIE
- 13 Feb 2018 — APPROVED FOR PUB - PRINCIPAL REGISTER